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Background. The risks associated with performing a percuta-
neous renal biopsy have substantially decreased in the past two
decades because of technical advances in the method. How-
ever, bleeding complications still occur, resulting in increased
hospital stay and treatment costs.
Methods. We investigated the predictive value of demo-
graphics (age, gender), clinical data (blood pressure), baseline
chemistry (hemoglobin/hematocrit, prothrombin time, partial
thromboplastin time, bleeding time, serum creatinine, daily pro-
teinuria), and needle size for the risk of major (need for blood
transfusion, nephrectomy, or angiography) or minor (no need
for any intervention) postrenal biopsy bleeding complications.
This was a prospective cohort study of 471 patients who under-
went ultrasound-guided biopsy of native kidney by automated
needle in a single center; all biopsies were performed by two ex-
perienced nephrologists. Patients with transplant kidneys were
excluded from the study. Predictors of postbiopsy bleeding were
assessed by multiple linear and multivariate logistic regression
analysis. Data are presented as unadjusted (OR) and adjusted
odds ratios (AOR) with 95% confidence intervals (CI).
Results. The study cohort consisted of 471 (277 males, 194 fe-
males) patients. Of these, 161 (34.1%) experienced postbiopsy
bleeding [157 (33.3%) hematomas, 2 (0.4%) gross hematuria, 2
(0.4%) arteriovenous fistula]. Major complications were seen in
6 (1.2%) patients (blood transfusion, N = 2; angiography, N = 3;
nephrectomy, N = 1), but no deaths occurred. The risk of post-
biopsy bleeding was higher in women (39.7% women, 30.3%
men, AOR 2.05, 95% CI 1.26 to 3.31, P = 0.004), younger sub-
jects (35.0 ± 14.5 years vs. 40.3 + 15.4, AOR 0.80, CI 0.68 to 0.94,
P = 0.006), and patients with higher baseline partial thrombo-
plastin time (102.7 + 11.8% vs. 100.1 + 10.0%, AOR 1.26, CI
1.02 to 1.54, P = 0.032). These findings were independent of size
of hematoma.
Conclusion. Although the methods for performing a percuta-
neous renal biopsy have improved in the past two decades, renal
biopsy is still not a risk-free procedure. Of the data routinely
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collected for potential predictors of postbiopsy bleeding com-
plications, only gender, age, and baseline partial thromboplastin
time show a significant predictive value. The other variables in-
vestigated do not have any predictive value.
Renal biopsy is an essential procedure in the di-
agnosis of primary and secondary renal diseases. The
technique has significantly improved over the past two
decades because of the introduction of ultrasonography
and automated-gun biopsy devices. Sonographic assis-
tance enables skin-surface marking of the lower pole, and
real-time ultrasound guidance allows visualization of the
biopsy needle and its path during the procedure [1, 2].
Retrospective and noncontrolled studies have shown that
real-time ultrasound-guided percutaneous renal biopsy
performs better than freehand renal biopsy. Likewise,
automated-gun biopsy devices are easy to use and less
risky than conventional manual puncture methods [3–12].
A randomized controlled trial has confirmed the better
performance of automated compared with manual renal
biopsy procedures [13].
Despite the simplicity of the procedure and the fre-
quency with which biopsies are routinely performed
in nephrology units, we still do not know exactly
what the rate of postbiopsy bleeding complications is.
Many baseline demographic, clinical, chemistry find-
ings, and other data (e.g., age, gender, blood pres-
sure, hemoglobin/hematocrit, prothrombin time, partial
thromboplastin time, bleeding time, serum creatinine,
daily proteinuria, type and size of needle used) are col-
lected prior to the renal biopsy, but no study has shown
that all these are necessary to predict postbiopsy bleeding.
The available studies have only investigated the question
using univariate comparisons. For example, the baseline
hemoglobin or blood pressure level of subjects who pre-
sented with postbiopsy bleeding was compared with those
in subjects who did not experience bleeding. The results
were not adjusted for other baseline conditions that could
affect the outcome (i.e., potential confounders) [13, 14,
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15]. Only one study used multivariate regression analysis
to analyze the data from a mixed prospective and retro-
spective cohort [16].
The aim of our study was to evaluate the incidence of
postbiopsy bleeding complications in a prospective co-
hort of patients who underwent real-time ultrasound-
guided automated percutaneous renal biopsy of native
kidney in a single nephrology center. We also tried to as-
sess the risk of postbiopsy bleeding complications and the
factors that predict it.
METHODS
Study population
The present analysis includes all patients who under-
went renal biopsy of native kidney in the Department of
Emergency and Organ Transplantation, the University of
Bari, Italy, from January 1995 to December 2002. Trans-
plant kidney biopsies were excluded from this study, and
renal biopsies were only performed on kidneys that were
more than 9 cm in length. Two experienced nephrolo-
gists (CM, LG) performed all the biopsies. Patients were
admitted the day prior to the biopsy and observed for
at least 48 hours postbiopsy [15, 16]. A 14- or 16-gauge
automated spring-loaded gun was used for the biopsy,
depending on availability from the supply store of the
hospital. All biopsies were performed using real-time
ultrasound-fixed guidance (3.5 MHz convex probe, AU
570; Esaote, Italy, which is able to detect hematomas of
a few mm thickness) by a nephrologist with assistance
from an expert in renal ultrasonography (NC). A pathol-
ogist promptly examined the biopsy specimen under a
light microscope to confirm that sufficient renal tissue was
available for light, immunofluorescence, and electron mi-
croscopy studies. Oral nifedipine was administered prior
to renal biopsy to all patients with a blood pressure read-
ing >140/90 mm Hg. Blood transfusions and 1-deamino-
8-D-arginine vasopressin (DDAVP) were administered
to patients with abnormal bleeding times (>7 minutes).
Following the biopsy, patients lay in bed on their backs
for a 24-hour observation time. During this time, both
clinical (gross hematuria, flank pain, hypotension) and
ultrasound evaluations (presence/absence of hematoma,
size, location) were performed to identify those patients
with bleeding complications.
Definitions
Postbiopsy bleeding complications were categorized
as either minor or major. Minor complications in-
cluded gross hematuria and/or subcapsular perinephric
hematoma (<5 cm diameter) that spontaneously resolved
without need for further intervention. Major compli-
cations were defined as those that required an inter-
vention for resolution, either the transfusion of blood
products or an invasive procedure (angiography,
surgery), and those that led to acute renal obstruction
or failure, septicaemia, or death. The size of postbiopsy
hematomas (surface area) was defined as the product
of the longest and the shortest diameters on the two-
dimensional sonographic pictures.
Variables
The following data were prospectively collected for all
patients: baseline demographics (age, gender), type of
kidney (native or transplant), indication for renal biopsy
[urinary abnormalities (i.e., proteinuria and hematuria),
or recurrent macrohematuria, nephrotic syndrome, acute
or chronic renal failure], baseline and postbiopsy sys-
tolic and diastolic blood pressure, baseline and 24-hour
postbiopsy serum creatinine, hemoglobin and hema-
tocrit, baseline coagulation parameters (prothrombin
time, partial thromboplastin time, bleeding time), 24-
hour prebiopsy urinary protein excretion, and needle
size (14 or 16 gauge). In addition, information regarding
any postbiopsy bleeding complications (gross hematuria,
haematoma, arteriovenous fistula), number of passes,
number of cores, and number of total glomeruli in the
biopsy were collected. All data were double-entered in a
relational database (LA, GS), and data entry was checked
by a third investigator at the time of data analysis (NC).
Statistical analysis
Results are expressed as mean ± SD or median and
interquartile range (IQR) for continuous data, and as in-
tegers, frequencies, and percentages for categorical data.
Baseline characteristics of individuals who did or did not
present with postbiopsy bleeding were compared by one-
way analysis of variance (ANOVA), Kruskal-Wallis test,
unpaired and paired Student t test, Mann-Whitney U
test for continuous data, and the chi-square statistic for
categorical data. The variability in number of bleeding
complications by age was evaluated using the Mantel-
Haenszel chi-square test for trend. Significant indepen-
dent predictors of postbiopsy bleeding were determined
by linear regression and multiple logistic regression anal-
ysis. This model was used because the outcome variable of
interest is categorical. For the purpose of all analyses, the
following variables were recoded: serum creatinine (re-
nal failure was defined as serum creatinine >132 lmol/L)
and urinary protein excretion (nephrotic proteinuria was
defined as urinary protein excretion >3.0 g/24 h). Sig-
nificant independent variables were identified by a step-
wise approach. Covariates with P < 0.20 or which were
clinically relevant were retained in the final model of ad-
equate statistical power (at least 15 subjects for each vari-
able). Risk estimates were presented as unadjusted (OR)
and adjusted odds ratios (AOR) and 95% confidence in-
tervals (CI). The Hosmer-Lemeshow statistic was used
for the final goodness-of-fit test for each logistic regres-
sion model.
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Table 1. Baseline demographic and clinical findings of 471 patients
who underwent percutaneous ultrasound-guided renal biopsy
Characteristic Measure
Number of patients 471
Age years 38.5 ± 15.3
Gender (male: female) 277: 194
Body weight kg 70.1 ± 10.9
Systolic blood pressure mm Hg 131.8 ± 16.6
Diastolic blood pressure mm Hg 84.3 ± 10.2
Hemoglobin g/L 130.0 ± 23.0
Hematocrit % 38.9 ± 6.6
Platelets number × 103/mm3 236 (196–278)
Fibrinogen g/L 3.8 ± 1.4
Bleeding time minutes 5.0 (4–6)
Prothrombin time % 98.1 ± 8.8
Partial thromboplastin time % 101.0 ± 10.7
Serum creatinine lmol/L 88.0 (70.4–132.0)
Proteinuria g/24 hr 1.1 (0.3–1.9)
Data are expressed as mean ± SD, median (interquartile range), or absolute
frequency.
The association between surface area of the hematoma
and potential predictors of postbiopsy bleeding was as-
certained by multiple linear regression using the surface
of hematoma as the dependent variable.
All analyses were performed using SAS, version 8.1
(SAS Institute, Cary, NC, USA) and SPSS for Win-
dows, release 11.5 (SPSS, Inc., North Sydney, Australia);
P < 0.05 was considered statistically significant.
Regulatory considerations
The study was performed according to recommenda-
tions outlined in the Declaration of Helsinki (IV Adap-
tation) [17]. Each patient was informed of the aims of the
study, the expected benefits, and the possible harms as-
sociated with the biopsy procedure. Participation in the
study was voluntary, and written informed consent was
obtained from all participants [18].
RESULTS
During the eight years of the study, data relating to
471 consecutive renal biopsy procedures of native kid-
ney were prospectively collected in the database. The
baseline demographic and clinical findings are summa-
rized in Table 1. Clinical indicators for renal biopsy
were the presence of urinary abnormalities (proteinuria,
hematuria) or recurrent macrohematuria (67.7 %, 319
patients), nephrotic syndrome (17.4 %, 82 patients), and
acute (4.0 %, 19 patients) or chronic (10.9 %, 51 patients)
renal failure. Final histologic findings in the overall co-
hort, stratified by the presence or absence of postbiopsy
bleeding complications, are shown in Table 2.
Incidence and characterization of postbiopsy
bleeding complications
Postbiopsy bleeding complications occurred in 34.1%
(161/471) of the study cohort. Gross hematuria was seen
Table 2. Comparative analysis of histologic diagnosis of patients who
did and did not present with post biopsy bleeding complications
Patients
Patients with without
Overalla complications complications
Diagnosis N % N % N %
Glomerulonephritis 358 76.0 120 33.5 238 66.5
IgA nephropathy 211 44.8 81 38.4 130 61.6
Membranous GN 41 8.7 11 26.8 30 73.2
Focal sclerosing GN 20 4.2 5 25.0 15 75.0
Minimal change GN 15 3.2 3 20.0 12 80.0
Rapid progressive GN 21 4.5 1 4.8 20 95.2
Lupus nephritis 26 5.5 11 42.3 15 57.7
Endocapillary GN 14 3.0 4 28.6 10 71.4
Membranoproliferative GN 10 2.1 4 40.0 6 60.0
Interstitial nephritis 17 3.6 3 17.6 14 82.3
Vascular kidney diseases 33 7.0 13 39.4 20 60.6
Benign nephrosclerosis 23 4.9 8 34.8 15 65.2
Thrombotic microangiopathy 4 0.8 0 0.0 4 100.0
Vasculitis 6 1.3 5 83.3 1 16.7
Miscellaneous 63 13.4 25 39.7 38 60.3
Amyloidosis 9 1.9 4 44.4 5 55.5
Diabetic nephropathy 7 1.5 2 28.6 5 71.4
End-stage kidney disease 24 5.1 10 41.7 14 58.3
Others 23 4.8 9 39.1 14 60.9
Total 471 100 161 34.1 310 65.8
av 2 3 = 3.38, P = 0.33, for comparison of the proportion of patients with
diagnoses of glomerulonephritis, interstitial nephritis, vascular kidney disease, or
miscellanous, with or without bleeding complications.
in 0.4% (2/471), arteriovenous fistula in 0.4% (2/471),
and hematoma in 33.3% (157/471) of patients. The mean
surface area of hematomas was 289.6 mm2 (SD 205.6
mm2). Median value was 233.0 mm2 (IQR 145.0 to 350.0
mm2). Postbiopsy renal hematomas were clinically silent
in many (142/157, 90.4%) patients, and lumbar pain was
present in only 2.5% (12/471) of subjects. Minor com-
plications were seen in 32.9% (155/471) of patients, and
major complications seen in 1.2% (6/471). The six major
complications were two cases of arterovenous fistulas and
four hematomas. Two of the six patients required blood
transfusions for relevant hemoglobin decline >40 g/L,
with cardiovascular instability, hypotension, and tachy-
cardia. Three patients underwent angiographic evalua-
tion of the bleeding and gel-foam transarterial catheter
embolization of the lesion (bleeding or arteriovenous fis-
tula), and one patient underwent a nephrectomy. This
patient had systemic lupus erythematosus and presented
with rapidly progressive oligo-anuric renal insufficiency.
The patient had received pulse steroids and cyclophos-
phamide, dialysis, and plasmapheresis two weeks prior to
the renal biopsy, with no significant improvement. The
renal biopsy documented severe diffuse proliferative lu-
pus nephritis (class IV) with intracapillary and arteriolar
thrombosis and the presence of extensive fibrous cres-
cents. The decision to perform a nephrectomy was made
because of a large hematoma, the patient’s severe ane-
mia, and the low likelihood of renal recovery as per the
renal biopsy findings. There were no deaths. Of patients
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Table 3. Distribution of potential predictors of bleeding in patients
who did or did not present with postbiopsy bleeding complications
Value in Value in
patients with patients without
Item complications complications P value
Number of patients 161 310 NA
Age years 35.0 ± 14.5 40.3 ± 15.4 0.001
Gender male, N (%) 84 (30.3) 193 (69.7) 0.034a
Female, N (%) 77 (39.7) 117 (60.3) -
Systolic blood
pressure mm Hg
130.9 ± 16.1 132.3 ± 16.8 0.399
Diastolic blood
pressure mm Hg
83.9 ± 11.1 84.6 ± 9.7 0.531
Body weight kg 68.9 ± 10.8 70.7 ± 11.0 0.098
Pre-hemoglobin g/L 132.0 ± 22.0 129.0 ± 23.0 0.114
Post-hemoglobin
g/L
125.0 ± 21.0 125.0 ± 23.3 0.687
 Hemoglobin g/L 7.0 ± 9.0 4.0 ± 9.0 0.002
Platelets number ×
103/mm3
228 (190–280) 238 (201–277) 0.124
Fibrinogen g/L 3.6 ± 1.4 3.8 ± 1.4 0.182
Bleeding time
minutes
5.0 (4.0–6.0) 5.0 (4.0–6.0) 0.690
Prothrombin time % 97.9 ± 8.9 98.3 ± 8.7 0.631
Partial
thromboplastin
time %
102.7 ± 11.8 100.1 ± 10.0 0.013
Serum creatinine
lmol/L
88.4 (70.7–123.8) 97.2 (79.6–132.6) 0.138
Proteinuria g/24 hr 1.0 (0.3–1.9) 1.1 (0.4–2.0) 0.251
Needle 14-gauge,
N (%)
96 (34.9) 179 (65.1) 0.694b
Needle 16-gauge,
N (%)
65 (33.2) 131 (66.8) -
NA, not applicable. Data are expressed as mean ± SD, median (interquartile
range), absolute, or percent frequency; comparisons between groups were made
by one-way analysis of variance (ANOVA), Kruskall-Wallis test, unpaired t test,
Mann-Whitney U test, or chi-square test.
aFor female vs. male gender.
bFor 16- vs. 14-gauge needle.
with amyloidosis (N = 9), five had mild-moderate renal
failure with normal or slightly increased renal size.
Assessment of potential predictors of postbiopsy
bleeding complications
Data for the various potential predictors of postbiopsy
bleeding complication are presented in Table 3. There
was a significantly greater proportion of women (39.7%)
compared with men (30.3%) who developed postbiopsy
bleeding complications (P = 0.001). There was also a
variable distribution in the risk of postbiopsy bleed-
ing according to age (Fig. 1), with postbiopsy bleeding
occurring more frequently in the younger age groups (11
to 20, 21 to 30 years). The trend for fewer postbiopsy
bleeding complications with increasing age was highly
statistically significant (trend v 21 = 18.64, P < 0.0001),
and not explained by significant differences in the final
histologic diagnosis (Table 2, v 23 = 3.38, P = 0.33). Base-
line partial thromboplastin time was significantly higher
in patients who developed postbiopsy bleeding compli-
cations compared with those who did not (102.7 ± 11.8%
vs. 100.1 ± 10.0%, P = 0.013) (Table 3). Of all the patients
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Fig. 1. Distribution of 161 cases of postbiopsy bleeding complications
in seven age categories. Data are from a cohort of 471 patients.
in our cohort, three had a baseline partial thromboplas-
tin time above the normal range, two with a moderate
deficit of factor VIII (renal biopsy was performed follow-
ing DDAVP administration, with no complications), and
one with antiphospholipids syndrome and lupus antico-
agulants (the patient presented an arteriovenous fistula
following biopsy, which resolved with angiography and
embolization). Two patients with moderate von Wille-
brand’s factor deficiency and nine with moderate renal
failure had abnormal baseline bleeding times. These sub-
jects received blood transfusions and DDAVP so that
all patients had a normal bleeding time prior to biopsy.
No patient was receiving nonsteroidal anti-inflammatory
drugs, antiplatelet agents, or antihistamines at the time of
biopsy. No other baseline chemistry was significantly dif-
ferent across the two groups. There was also no significant
difference in the other considered baseline patient char-
acteristics or needle type between those who did or did
not present with postbiopsy bleeding complications. As
expected, a greater change between pre- and postbiopsy
hemoglobin concentration was observed in patients who
developed bleeding complications compared with those
who did not ( hemoglobin 7.0 ± 9.0 g/L vs. 4.0 ± 9.0 g/L,
P = 0.002).
Adequacy of renal sampling
There were no cases of inadequate sampling. There
was no significant difference in the number of passes
(median = 2, IQR = 2–2 for both groups, P = 0.309), cores
(median = 2, IQR = 1–2 for both groups, P = 0.056), or
total glomeruli obtained (median = 14, IQR = 10–18 vs.
median = 14, IQR = 10–20, P = 0.765) between patients
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Table 4. Unadjusted and adjusted risk estimates of postbiopsy bleeding complications in 471 biopsies of native kidney
Value in patients Value in patients Unadjusted Adjusted
Unit of with complications without complications odds ratio odds ratio
Risk factor increase (N = 161) (N = 310) (95% CI) (95% CI) P value
Age years 10 35.0 ± 14.5 40.3 ± 15.4 0.81 (0.71–0.92) 0.80 (0.68–0.94) 0.006
Female sex, N (%) NA 77 (39.7) 117 (60.3) 1.51 (1.03–2.22) 2.06 (1.27–3.34) 0.004
Systolic blood pressure mm Hg 1 130.9 ± 16.1 132.3 ± 16.8 0.99 (0.98–1.01) 1.01 (0.99–1.02) 0.480
Prebiopsy hemoglobin g/L 10 132.0 ± 22.0 129.0 ± 23.0 1.07 (0.98–1.17) 1.11 (0.98–1.25) 0.111
Platelets number × 103/mm3 105/mm3 228 (190–280) 238 (201–277) 0.85 (0.66–1.08) 0.81 (0.62–1.06) 0.132
Fibrinogen g/L 1 3.6 ± 1.4 3.8 ± 1.4 0.91 (0.79–1.05) 0.98 (0.83–1.17) 0.849
Bleeding time minutes 1 5.0 (4.0–6.0) 5.0 (.0–6.0) 1.02 (0.88–1.18) 0.99 (0.85–1.18) 0.988
Prothrombin time % 10 97.9 ± 8.9 98.3 ± 8.7 0.95 (0.76–1.18) 0.82 (0.64–1.07) 0.142
Partial thromboplastin time % 10 102.7 ± 11.8 100.1 ± 10.0 1.25 (1.05–1.50) 1.25 (1.02– 1.53) 0.032
Serum creatinine ≥132 lmol/L % 0 = no; 38 (23.6) 83 (26.8) 0.85 (0.54–1.31) 1.42 (0.80–2.48) 0.225
1 = yes
Proteinuria >3.0 g/24 hr % 0 = no; 20 (12.4) 61 (19.7) 0.58 (0.34–0.99) 0.70 (0.38–1.28) 0.241
1 = yes
Number of passes 1 96 (34.9) 179 (65.1) 0.82 (0.54–1.24) 0.78 (0.51–1.21) 0.269
Needle 14-gauge NA 65 (33.2) 131 (66.8) 1.08 (0.73–1.59) 0.95 (0.62–1.44) 0.796
NA, not applicable. Data are expressed as odds ratio and 95% confidence intervals.
who did or did not present with postbiopsy bleeding. Fur-
thermore, no differences were seen for 14- or 16-gauge
needles in terms of passes (median = 2, IQR = 2–2 for
both groups, P = 0.204), cores (median = 2, IQR = 1–2
for both groups, P = 0.689), and number of glomeruli in
the obtained specimen (median = 14, IQR = 10–18 vs.
median = 14, IQR = 9–20, P = 0.372) between the two
outcome groups. There was no significant difference in
the complication rate for the two nephrologists who per-
formed the biopsies (34.6% vs. 33.1%, v 2 = 0.104, P =
0.747).
Univariate and multivariate analysis of predictors
of postbiopsy bleeding complications
Unadjusted and adjusted estimates of the association
between different risk factors and bleeding complications
are reported in Table 4. Thirteen variables (age, gender,
systolic blood pressure, prebiopsy hemoglobin, platelet
count, fibrinogen, bleeding time, prothrombin time, par-
tial thromboplastin time, presence or absence of renal
failure or nephrotic proteinuria, needle size, and num-
ber of passes) were included in the final model. There
was a strong association between postbiopsy bleeding
and female gender (AOR 2.05; 95% CI 1.26–3.31; P =
0.004) and higher baseline partial thromboplastin time
(AOR 1.26, 95% CI 1.02 to 1.54, P = 0.032, for every
10% increase of baseline partial thromboplastin time).
In addition, the risk of postbiopsy bleeding significantly
decreased for every 10-year increase in age (AOR 0.80,
95% CI 0.68–0.94, P = 0.006).
Relationship between predictors of postbiopsy bleeding
and surface area of hematomas
In patients with major complications (two arteri-
ovenous fistulas and four hematomas), the areas of
hematomas (107.0, 290.0, 650.0, and 738.0 mm2, respec-
tively; mean 421.2 mm2, SD 267.9 mm2, median 464.0
mm2, IQR 198.5–644.0 mm2) were generally, but not al-
ways higher than those of patients with minor compli-
cations (mean 285.4 mm2, SD 202.1 mm2, median 230.0
mm2, IQR 147.5–342.0 mm2). There was no significant
relationship between any of the factors considered in
the present analysis and the surface area of postbiopsy
hematomas (i.e., though age, female sex, and baseline
partial thromboplastin time predicted postbiopsy bleed-
ing, they were not associated with surface area of the
hematoma) (Table 5).
DISCUSSION
Key findings
In this cohort of 471 patients followed in a sin-
gle center, the incidence of postrenal biopsy bleeding
complications detected by ultrasonography and clinical
examination was relatively high (34.1%), although bleed-
ing complications were generally not worrisome, with
only 1.2% requiring interventions (major complications).
Clinical signs (discomfort or lumbar pain) were present in
only a small proportion (N = 12, 2.5%) of our cohort. Of
several routinely collected demographic, clinical, chem-
istry, and needle-related indicators, only gender, age, and
baseline partial thromboplastin time were found to be
significantly predictive of the risk of postbiopsy bleed-
ing. This risk was greater in women (39.7% of women
vs. 30.3% of men, AOR 2.05, 95% CI 1.26–3.31, P =
0.004) and patients with higher baseline partial throm-
boplastin times (AOR 1.26, 95% CI 1.02–1.54, P = 0.032,
for every 10% increase in baseline partial thromboplas-
tin time). Conversely, for every 10-year increase in age,
the risk of postbiopsy bleeding complications was signif-
icantly lower (AOR 0.80, 95% CI 0.68–0.94, P = 0.006).
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Table 5. Multiple linear regression of the association of potential
predictors of postbiopsy bleeding complications and size of
hematomaa
Unstandardized Standardized P
Risk factor coefficient (B) coefficient (Beta) value
Age (10 years) 15.7 −0.11 0.257
Female sex % 41.7 0.10 0.295
Systolic blood
pressure mm Hg
1.42 0.11 0.236
Prebiopsy
hemoglobin g/L
7.09 0.075 0.495
Platelets number ×
103/mm3
−15.31 0.059 0.491
Fibrinogen g/L 1.36 0.009 0.925
Bleeding time
minutes
−17.94 −0.106 0.248
Prothrombin time % 9.08 0.040 0.688
Partial
thromboplastin
time %
−1.81 −0.011 0.913
Serum creatinine
≥132 lmol/L %
−37.87 −0.079 0.418
Proteinuria >3.0
g/24 hr %
−67.51 −0.107 0.245
Number of passes 58.38 0.13 0.120
Needle 14-gauge 16.01 0.038 0.656
Data are expressed as regression coefficients and P values.
aDependent variable (surface area expressed in mm2); multiple R = 0.259,
P = 0.675.
Though age, female sex, and baseline partial thrombo-
plastin time predicted postbiopsy bleeding, they were not
associated with surface area of the hematoma.
Comparison with existing knowledge
The majority of published studies on this topic have
focused on the comparative performance of different re-
nal biopsy techniques and types of needles [2, 8, 10, 11,
20–22]. They were all retrospective nonrandomized anal-
yses and suggested that automated smaller needles (16-
or 18-gauge compared with the 14-gauge needle) reduced
the complication rate. The results of these studies are
likely to reflect the impact of biopsy technique rather
than needle size [10, 11, 22]. The use of 14- versus 18-
gauge in native kidney renal biopsies has been compared
in a randomized trial that showed a greater incidence
of complications in manual biopsy with 14-gauge needle
compared with automated renal biopsy using 18-gauge
guns [13]. None of these studies looked at which factors
significantly predict postbiopsy bleeding. One published
analysis prospectively evaluated a sample of 523 biop-
sies performed with an automated 14-gauge needle un-
der real-time ultrasound guidance, but also included ret-
rospective data of 227 biopsies, and ultrasound follow-up
of all biopsies was not performed [16]. Minor compli-
cations were reported in 6.7% of all renal biopsies and
major complications in 6.4% [16].
Another retrospective review of 9595 biopsies per-
formed over a period of 50 years found an average in-
cidence of clinically relevant complications of 7.4%. Of
these, only 0.3% required angiographic or surgical inter-
vention [19]. Death occurred in <0.1% of cases. Com-
parison between these data and ours is difficult because
of the different methodology used. We found a higher
incidence of bleeding complications. We also observed
major complications in only six (1.2%) patients, blood
transfusions being required in two patients and invasive
procedures required in four patients.
Weaknesses and strengths of our study
We did not evaluate the effect of difference in nee-
dle size or technique of lower pole localization because
automated gun biopsy under real-time ultrasound guid-
ance is considered the reference standard procedure.
These differences would be better ascertained by ran-
domized controlled trials. One limitation of our study is
the cohort design, but this is the only possible design that
can answer the proposed question. We analyzed, for the
first time, a large cohort of biopsies performed in a sin-
gle center by two experienced nephrologists using auto-
mated devices and ultrasound guidance. Only prospective
data were studied. Although retrospective information
on 1720 biopsies performed by various techniques before
1995 was available, these were excluded, something that
other studies did not do [16, 19]. These criteria were set “a
priori” with the knowledge that cohort studies are prone
to unpredictable bias and confounding by unknown fac-
tors and retrospective data analysis would only add to
this risk. We also used multivariate analysis to ascertain
the factors that contribute to postbiopsy bleeding compli-
cations. This analysis, which has not been systematically
done on prospective data in any previous report, allows
for adjusting for potential known confounders, although
unknown factors may not be accounted for. Neverthe-
less, the single center cohort design limits the external
validity of our findings, and it is plausible that giving pa-
tients antihypertensive agents and DDAVP before their
renal biopsies may have altered the patterns of postbiopsy
bleeding complications, even though this is standard prac-
tice. Finally, this study has also identified the significant
independent predictors of primarily clinically insignifi-
cant bleeding complications, and our data indicate that
age, female sex, and baseline partial thromboplastin time
predict postbiopsy bleeding, but are not associated with
surface area of the hematoma. This may be due to the
small number of major complications (1.2%) observed in
this study, and whether or not these same parameters are
also important predictors of the major episodes of bleed-
ing requiring intervention is uncertain. However, minor
bleeding complications are also very important because
of significant costs, increased hospitalization time, and
impairment of patients’ utilities that are associated with
them.
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Implications for clinical practice and rationale
Automated needle biopsy under fixed-ultrasound guid-
ance appears to be a safe procedure. Although the rate
of bleeding complications in our study was relatively high
(about one third of all procedures) when systematically
detected with ultrasound guidance and clinical analysis,
almost all proved to be minor complications, with ma-
jor complications occurring in only 1.2% of patients. Of
the information routinely collected at the time of renal
biopsy there appeared to be no truly reliable indicators of
adverse outcome. Only gender, baseline partial thrombo-
plastin time, and age show independent predictive value
for postbiopsy bleeding. The increased risk of postbiopsy
bleeding in women may be explained by their different
body composition. The greater percentage of fat mass
in women may be responsible for a tendency to hemor-
rhagic enlargement into perirenal tissues. As for base-
line partial thromboplastin time, the fact that even small
increases (within the normal range, and thus, not clin-
ically significant) are a reliable predictor of postbiopsy
bleeding raises the question of which are the critical val-
ues and whether other coagulation indicators are also
important. In current practice, we also generally com-
bine coagulation assays with evaluation of bleeding time
when making a decision about performing a renal biopsy.
Bleeding time was not significantly predictive in this anal-
ysis and has been reported to have substantial limitations
as a screening test; it should be performed by the same op-
erator to avoid interobserver variability. Given a positive
predictive value of 5% for bleeding time in unselected
populations, false negatives may lead to a false sense of
security [23, 24], and it has been suggested that the current
use of bleeding time may be unsatisfactory. The empiric
treatment of all patients with prebiopsy DDAVP may be
useful [25–27], especially those with chronic renal fail-
ure (GFR <30 mL/min). Finally, although the increased
risk of postbiopsy bleeding with younger age is difficult
to explain and clinically counterintuitive, it suggests that
postbiopsy bleeding complications should be watched for
in the young, as well as in the elderly.
Implications for research
Given these findings, are there any direct implications
for clinical research? It appears at present that we have no
definite predictive indicators of postbiopsy bleeding com-
plications, with the exception of age and gender, which
are a “given” (and we do not need to spend any money
to detect), and the baseline partial thromboplastin time.
Increased values of baseline partial thromboplastin time,
which significantly predicted postbiopsy bleeding in this
study, were still in the “normal” range, raising the issue of
what is the critical value when preparing for renal biopsy.
Whether collection of large amounts of costly informa-
tion and examinations besides these is necessary prior
to any renal biopsy procedure is still to be proven. It is
also likely that ultrasonography has brought about an
overdetection of inconsequential hematomas. It would
be useful to systematically identify a threshold between
the benefits of outcome detection (hematoma) and util-
ities (informing the patient of a bleeding complication
raises anxiety and, although not clinically relevant, most
biopsy complications increase the observation time, and
their follow-up implies costly imaging procedures and
chemistry investigations). Lastly, because bias (selection
and other) is unpredictable in a cohort analysis, the clin-
ically counterintuitive findings of this study, such as the
association between younger age and increased risk of
postbiopsy bleeding, need to be further explored. Doc-
umenting similar strong associations in more than
one cohort analysis would make this hypothesis more
plausible.
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